Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Watchdog Group Seeks FDA Ban of Antifungal Tablets

By Drug Discovery Trends Editor | February 25, 2015

A consumer safety group is calling on the Food and Drug Administration to pull certain antifungal tablets off the market, saying there are safer medicines that do not carry risks of liver damage.
 
Public Citizen filed a petition Tuesday asking the FDA to ban ketoconazole tablets, which are used against hard-to-treat fungal infections.
 
First approved in 1981, the drug has long carried a boxed warning about potentially fatal liver damage. In July 2013 the FDA restricted ketoconazole’s use to infections that do not respond to other drugs. The agency also required that all patients filling a prescription receive a medication guide detailing the drug’s risks.
 
But Public Citizen notes that European regulators went further, recommending that all oral versions of the drug be removed from the market. Additionally, the consumer watchdog group points to an internal FDA memo in which 14 scientists from the agency’s surveillance unit conclude that ketoconazole’s risks outweigh its benefits. Those findings were delivered at an agency workshop in January 2013, six months before the FDA decided to restrict the drug’s use, but keep it on the market.
 
Last year U.S. patients filled 462,000 prescriptions for the drug, according to data cited by Public Citizen.
 
“Unless the FDA bans oral ketoconazole, its continued marketing will result in hundreds of preventable cases of serious liver damage a year,” states the group’s petition.
 
Ketoconazole is also available in topical formulations, though Public Citizen says those versions do not carry the risks cited in the petition.
 
Tablets of the drug are sold by generic drugmakers Teva Pharmaceuticals and Mylan Inc.

Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50